肾移植术后局灶节段性肾小球硬化复发的研究进展

刘莉莉; 孙启全

doi:10.3969/j.issn.1674-7445.2018.04.015

肾移植术后局灶节段性肾小球硬化复发的研究进展

doi: 10.3969/j.issn.1674-7445.2018.04.015

刘莉莉,
孙启全^,

100730 北京医院肾内科国家老年医学中心（刘莉莉）；中山大学附属第三医院肾移植科（孙启全）

基金项目:

国家自然科学青年基金 81200523

首都临床特色应用研究项目 Z151100004015083

国家科技重大新药创制专项 2017ZX09304026

北京医院121工程项目 121-2016008

详细信息

作者简介:
刘莉莉，女，1981年生，博士，研究方向为肾小球疾病，Email:lll_9536@163.com

通讯作者:
孙启全，男，1973年生，博士，主任医师，研究方向为肾移植相关疾病，Email:sunqiq@mail.sysu.edu

中图分类号: R617
计量
- 文章访问数: 139
- HTML全文浏览量: 149
- PDF下载量: 11
- 被引次数: 0
出版历程
- 收稿日期: 2018-05-16
- 网络出版日期: 2021-01-19
- 刊出日期: 2018-07-15

摘要

摘要: 局灶节段性肾小球硬化（FSGS）患者肾移植术后容易复发，是导致移植肾失功的重要原因之一。从循环因子学说到近年对足细胞靶抗原的认识，移植后FSGS复发的机制研究越来越深入，而针对足细胞抗原的靶向治疗也显示出广泛的应用前景。本文就肾移植术后FSGS的临床分型及危险因素、FSGS复发的机制、FSGS复发的预防和治疗进行综述。
- 肾移植 /
- 局灶节段性肾小球硬化 /
- 复发 /
- 足细胞 /
- 蛋白尿 /
- 循环因子 /
- 血浆置换

HTML全文

参考文献(22)

[1]	MESSINA M, GALLO E, MELLA A, et al. Update on the treatment of focal segmental glomerulosclerosis in renal transplantation[J]. World J Transplant, 2016, 6(1): 54-68. DOI: 10.5500/wjt.v6.i1.54.
[2]	D' AGATI VD, KASKEL FJ, FALK RJ. Focal segmental glomerulosclerosis[J]. N Engl J Med, 2011, 365(25): 2398-2411. DOI: 10.1056/NEJMra1106556.
[3]	PONTICELLI C, GLASSOCK RJ. Posttransplant recurrence of primary glomerulonephritis[J]. Clin J Am Soc Nephrol, 2010, 5(12): 2363-2372. DOI: 10.2215/CJN.06720810.
[4]	VINAI M, WABER P, SEIKALY MG. Recurrence of focal segmental glomerulosclerosis in renal allograft: an in-depth review[J]. Pediatr Transplant, 2010, 14(3): 314-325. DOI: 10.1111/j.1399-3046.2009.01261.x.
[5]	JUNGRAITHMAYR TC, HOFER K, COCHAT P, et al. Screening for NPHS2 mutations may help predict FSGS recurrence after transplantation[J]. J Am Soc Nephrol, 2011, 22(3): 579-585. DOI: 10.1681/ASN.2010010029.
[6]	SHARMA M, SHARMA R, MCCARTHY ET, et al. " The FSGS factor:" enrichment and in vivo effect of activity from focal segmental glomerulosclerosis plasma[J]. J Am Soc Nephrol, 1999, 10(3):552-561.
[7]	LE BERRE L, GODFRIN Y, GÜNTHER E, et al. Extrarenal effects on the pathogenesis and relapse of idiopathic nephrotic syndrome in Buffalo/Mna rats[J]. J Clin Invest, 2002, 109(4): 491-498. doi: 10.1172/JCI0212858
[8]	GALLON L, LEVENTHAL J, SKARO A, et al. Resolution of recurrent focal segmental glomerulosclerosis after retransplantation[J]. N Engl J Med, 2012, 366(17): 1648-1649. DOI: 10.1056/NEJMc1202500.
[9]	WEI C, EL HINDI S, LI J, et al. Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis[J]. Nat Med, 2011, 17(8): 952-960. DOI: 10.1038/nm.2411.
[10]	ALACHKAR N, WEI C, AREND LJ, et al. Podocyte effacement closely links to suPAR levels at time of posttransplantation focal segmental glomerulosclerosis occurrence and improves with therapy[J]. Transplantation, 2013, 96(7): 649-656. DOI: 10.1097/TP.0b013e31829eda4f.
[11]	SINHA A, BAJPAI J, SAINI S, et al. Serum-soluble urokinase receptor levels do not distinguish focal segmental glomerulosclerosis from other causes of nephrotic syndrome in children[J]. Kidney Int, 2014, 85(3): 649-658. DOI: 10.1038/ki.2013.546.
[12]	WADA T, NANGAKU M, MARUYAMA S, et al. A multicenter cross-sectional study of circulating soluble urokinase receptor in Japanese patients with glomerular disease[J]. Kidney Int, 2014, 85(3): 641-648. DOI: 10.1038/ki.2013.544.
[13]	MEIJERS B, MAAS RJ, SPRANGERS B, et al. The soluble urokinase receptor is not a clinical marker for focal segmental glomerulosclerosis[J]. Kidney Int, 2014, 85(3): 636-640. DOI: 10.1038/ki.2013.505.
[14]	DOYLE SL, OZAKI E, BRENNAN K, et al. IL-18 attenuates experimental choroidal neovascularization as a potential therapy for wet age-related macular degeneration[J]. Sci Transl Med, 2014, 6(230): 230ra44. DOI: 10.1126/scitranslmed.3007616.
[15]	REISER J, VON GERSDORFF G, LOOS M, et al. Induction of B7-1 in podocytes is associated with nephrotic syndrome[J]. J Clin Invest, 2004, 113(10): 1390-1397. doi: 10.1172/JCI20402
[16]	YU CC, FORNONI A, WEINS A, et al. Abatacept in B7-1-positive proteinuric kidney disease[J]. N Engl J Med, 2013, 369(25): 2416-2423. DOI: 10.1056/NEJMoa1304572.
[17]	GEBESHUBER CA, KORNAUTH C, DONG L, et al. Focal segmental glomerulosclerosis is induced by microRNA-193a and its downregulation of WT1[J]. Nat Med, 2013, 19(4): 481-487. DOI: 10.1038/nm.3142.
[18]	PONTICELLI C. Recurrence of focal segmental glomerular sclerosis (FSGS) after renal transplantation[J]. Nephrol Dial Transplant, 2010, 25(1): 25-31. DOI: 10.1093/ndt/gfp538.
[19]	GOHH RY, YANGO AF, MORRISSEY PE, et al. Preemptive plasmapheresis and recurrence of FSGS in high-risk renal transplant recipients[J]. Am J Transplant, 2005, 5(12): 2907-2012. doi: 10.1111/j.1600-6143.2005.01112.x
[20]	SALOMON R, GAGNADOUX MF, NIAUDET P. Intravenous cyclosporine therapy in recurrent nephrotic syndrome after renal transplantation in children[J]. Transplantation, 2003, 75(6): 810-814. doi: 10.1097/01.TP.0000055215.20367.21
[21]	FORNONI A, SAGESHIMA J, WEI C, et al. Rituximab targets podocytes in recurrent focal segmental glomerulosclerosis[J]. Sci Transl Med, 2011, 3(85): 85ra46. DOI: 10.1126/scitranslmed.3002231.
[22]	AUDARD V, KAMAR N, SAHALI D, et al. Rituximab therapy prevents focal and segmental glomerulosclerosis recurrence after a second renal transplantation[J]. Transpl Int, 2012, 25(5):e62-e66. DOI: 10.1111/j.1432-2277.2012.01462.x.